A RANDOMIZED PHASE 3 STUDY COMPARING FIRST-LINE PEMETREXED PLUS CISPLATIN FOLLOWED BY GEFITINIB AS MAINTENANCE WITH GEFITINIB MONOTHERAPY IN EAST ASIAN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSQNSCLC)

被引：0
|
作者：
Yang, James C. [1 ]
Park, Keunchil [2 ]
Mok, Tony Shu Kam [3 ]
Kang, Jin Hyoung [4 ]
Srimuninnimit, Vichien [5 ]
Lin, Chia-Chi [1 ]
Kim, Dong-Wan [6 ]
Tsai, Chun-Ming [7 ]
Barraclough, Helen [8 ]
Altug, Sedat [9 ]
Orlando, Mauro [10 ]
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Samsung Med Ctr, Seoul, South Korea
[3] Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
[4] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[5] Mahidol Univ, Div Med Oncol, Bangkok 10700, Thailand
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Taipei Vet Gen Hosp, Taipei, Taiwan
[8] Eli Lilly Australia, West Ryde, NSW, Australia
[9] Eli Lilly Instanbul, Istanbul, Turkey
[10] Eli Lilly Interamer Inc, Buenos Aires, DF, Argentina
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR; East-Asian patients; non-small cell lung cancer; pemetrexed;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO06.04
引用
收藏
页码：S288 / S288
页数：1
相关论文
共 50 条
  • [31] Maintenance therapy with gefitinib after first-line chemotherapy in patients affected by advanced non-small cell lung cancer
    Mencoboni, M.
    Bergaglio, M.
    Serra, M.
    Ivaldi, G. P.
    Tredici, S.
    Racchi, O.
    Rebella, L.
    Galbusera, V.
    Grosso, M.
    Faravelli, B.
    [J]. ANTICANCER RESEARCH, 2007, 27 (6C) : 4425 - 4429
  • [32] A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-Line Therapy for Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
    Schuette, Wolfgang H. W.
    Groeschel, Andreas
    Sebastian, Martin
    Andreas, Stefan
    Mueller, Thomas
    Schneller, Folker
    Guetz, Sylvia
    Eschbach, Corinna
    Bohnet, Sabine
    Leschinger, Monika I.
    Reck, Martin
    [J]. CLINICAL LUNG CANCER, 2013, 14 (03) : 215 - 223
  • [33] A Phase Ⅱ Trial of Gefitinib as Maintenance Therapy after First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in China
    Lu Yang 1
    1Department of Thoracic Medical Oncology
    [J]. Chinese Journal of Cancer Research, 2010, 22 (01) : 1 - 9
  • [34] Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Wielage, Ron
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Lawson, Anthony
    Schwartzberg, Lee
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) : 1263 - 1272
  • [35] Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
    Tsutani, Yasuhiro
    Miyata, Yoshihiro
    Masuda, Takeshi
    Fujitaka, Kazunori
    Doi, Mihoko
    Awaya, Yoshikazu
    Kuyama, Shoichi
    Kitaguchi, Soichi
    Ueda, Kazuhiro
    Hattori, Noboru
    Okada, Morihito
    [J]. BMC CANCER, 2018, 18
  • [36] Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
    Yasuhiro Tsutani
    Yoshihiro Miyata
    Takeshi Masuda
    Kazunori Fujitaka
    Mihoko Doi
    Yoshikazu Awaya
    Shoichi Kuyama
    Soichi Kitaguchi
    Kazuhiro Ueda
    Noboru Hattori
    Morihito Okada
    [J]. BMC Cancer, 18
  • [37] Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
    Kim, Young Hak
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) : 692 - +
  • [38] Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
    Kim, Young Saing
    Cho, Eun Kyung
    Woo, Hyun Sun
    Hong, Junshik
    Ahn, Hee Kyung
    Park, Inkeun
    Sym, Sun Jin
    Kyung, Sun Young
    Kang, Shin Myung
    Park, Jeong-Woong
    Jeong, Sung Hwan
    Park, Jinny
    Lee, Jae Hoon
    Shin, Dong Bok
    [J]. CANCER RESEARCH AND TREATMENT, 2016, 48 (01): : 80 - 87
  • [39] BIOMARKER ANALYSIS OF A RANDOMIZED, CONTROLLED, MULTICENTER CLINICAL TRIAL COMPARING PEMETREXED/CISPLATIN AND GMCITABINE/CISPLATIN AS FIRST-LINE TREATMENT FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Zhang, Li
    Huang, Yan
    Hu, Zhihuang
    Liu, Yun-Peng
    Zhou, Jianying
    Xu, Nong
    Li, Baolan
    Wu, Gang
    Liu, Xiaoqing
    Fang, Jian
    Li, Kai
    Wei, Liu
    Lu, You
    Wang, Meng-Zhao
    Liu, Wenzhao
    Liang, Houjie
    Zhang, Yiping
    Huang, Cheng
    Wang, Shunjin
    Wang, Yajie
    Yu, Shiying
    Chang, Jianhua
    Wang, Zhehai
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S330 - S330
  • [40] Phase III study of gefitinib (G) versus gefitinib plus carboplatin plus pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)
    Seike, M.
    Inoue, A.
    Sugawara, S.
    Morita, S.
    Hosomi, Y.
    Ikeda, S.
    Watanabe, K.
    Takahashi, K.
    Fujita, Y.
    Harada, T.
    Minato, K.
    Takamura, K.
    Kobayashi, K.
    Nukiwa, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 496 - 496
12345